Molecular marker for detection of prostate cancer and application thereof

A molecular marker, prostate cancer technology, applied in the field of genetic engineering, can solve the problems of difficult radical cure, inconspicuous enlargement of prostate cancer, missed diagnosis or misdiagnosis, etc.

Inactive Publication Date: 2017-03-29
叶伟亮
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, the limitations of digital rectal examination mainly lie in four aspects: (1) when the prostate mass is not large, it is easy to miss the diagnosis; (2) some patients have no obvious prostate cancer enlargement, but it is already at an advanced stage, and it is difficult to cure; (3) This test cannot be used when there is a disease in the rectum; (4) Inexperienced doctors may miss or misdiagnose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular marker for detection of prostate cancer and application thereof
  • Molecular marker for detection of prostate cancer and application thereof
  • Molecular marker for detection of prostate cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 High-throughput sequencing screening of differentially expressed genes

[0035] 1. Sampling

[0036] From October 2012 to December 2015, 27 tissue samples were obtained from the Department of Urology at Peking Union Medical College Hospital. All samples were confirmed by pathological examination, including 8 cases of paracancerous tissue samples and 19 cases of prostate cancer samples. Store in -80°C low temperature refrigerator.

[0037] 2. Total RNA extraction from tissue samples

[0038] use Reagent (invitrogen, Cat. No. 15596-018) was used to extract sample RNA, and the experimental operation was carried out according to the product manual. The specific operation was as follows:

[0039] After collecting the samples, freeze them in liquid nitrogen. After taking them out, put the tissue into a pre-cooled mortar for grinding. After the tissue sample is powdered:

[0040] ① Add Trizol and store at room temperature for 5 minutes;

[0041] ② Add 0.2 mL of...

Embodiment 2

[0050] Example 2 RT-PCR Verification of C2CD4D Expression in Prostate Cancer Tissue and Paracancerous Tissue

[0051] 1. Materials

[0052] 34 cases of prostate cancer tissue samples and 8 cases of paracancerous tissue samples were obtained from prostate cancer samples during urological surgery in Peking Union Medical College Hospital from 2012 to 2015, and they were grouped and numbered. All samples were confirmed by pathological examination.

[0053] 2. Method

[0054] 2.1 Extract the total RNA from the tissue sample, the same as the extraction method in Example 1.

[0055] 2.2 Synthesis of cDNA by reverse transcription

[0056] use III Reverse Transcriptase (invitrogen, Cat. No. 18080-044) was used for cDNA reverse transcription, and the experimental operation was carried out according to the product manual. The specific operation was as follows:

[0057] Using a reverse transcription kit, 1 μg of total RNA was reverse-transcribed with reverse transcription buffer to ...

Embodiment 3

[0076] Example 3 Gene chip verification of C2CD4D expression in prostate cancer tissue and paracancerous tissue samples

[0077] 1, the acquisition of material, with embodiment 2.

[0078] 2, the extraction of total RNA, with the method for embodiment 1.

[0079] 3. Gene chip verification

[0080] After the total RNA was linearized and amplified, the cy3-UTP labeled and fluorescently labeled cRNAs were purified using the RNEASY Mini Kit, and the labeled cRNAs were fragmented with Amhion’s RNA Fragmentation Reagents. Human whole gene expression profile chips (4x 44K genes) from Agilent Company of the United States were used, hybridized in a chip hybridization oven at 65°C for 17 hours, then eluted, stained, and finally scanned with an Agilent DNA MicroarrayScanner scanner.

[0081]After the hybridized chip reads the data points by the chip scanner, the data is imported into the analysis software, and the mRNAs whose natural logarithm absolute value of the ratio of the two gro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a molecular marker for detection of prostate cancer. The molecular marker is C2CD4D or expression protein of the mRNA and its fragment, analogue and derivative. The invention further discloses a method for the molecular marker to detect whether the prostate cancer related mRNA expression level is lowered. The invention also discloses a kit for diagnosis of prostate cancer, the kit includes specific amplification prostate cancer related mRNA's primers and specification, and the prostate cancer related mRNA is C2CD4D. As a molecular marker for prostate cancer detection, the C2CD4D enables more accurate and faster diagnose of prostate cancer. Also, the molecular marker provided by the invention provides a therapeutic target and important basis for gene therapy, drug therapy and other clinical application.

Description

technical field [0001] The invention relates to the field of genetic engineering, in particular to the use of C2CD4D associated with prostate cancer as a molecular marker for detecting prostate cancer and its application. Background technique [0002] Prostate cancer is one of the common male reproductive system malignancies. Worldwide, the incidence of prostate cancer ranks second among all malignant tumors in men. In the United States, the incidence of prostate cancer has surpassed that of lung cancer, becoming the first tumor that endangers men's health. The incidence of prostate cancer in Asia is far lower than that in European and American countries, but it has shown an upward trend in recent years, and the growth rate is faster than that in developed countries in Europe and America. Prostate cancer patients are mainly elderly men, usually after the age of 50, 95% occur in elderly men over 60 years old, and the incidence rate continues to increase with age. Prostate c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68C12N15/11G01N33/574A61K45/00A61P35/00
CPCC12Q1/6886A61K45/00C12Q2600/158G01N33/57434G01N33/57484
Inventor叶伟亮吴志宏邱宾涛
Owner叶伟亮